Loading...
Market
Will the European Commission approve Leqembi for early Alzheimer's by March 31, 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcement from the European Commission
Story
EMA Recommends Leqembi for Early Alzheimer's in Patients with ApoE4 Gene; Biogen Shares Rise 5%
Nov 14, 2024, 04:16 PM
The European Medicines Agency (EMA) has recommended the approval of Leqembi, a drug developed by Eisai and Biogen, for the treatment of early Alzheimer's disease. This decision comes after the agency initially rejected the treatment months prior. The recommendation was made by the Committee for Medicinal Products for Human Use (CHMP) and pertains specifically to patients with one or no copies of the ApoE4 gene. The drug has been shown to slow cognitive decline in these patients. Following the announcement, Biogen's shares rose by as much as 5%. The final verdict from the European Commission is still pending.
View original story
Similar markets
Yes • 50%
No • 50%
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
Approval in another major market • 25%
Rejection in another major market • 25%
Reapplication in the EU • 25%
No major decision • 25%
Canada • 25%
Australia • 25%
Germany • 25%
Other • 25%
